Equipment Supplement Requisition for Mesoscale Quick Plex SQ 120mm Reader

Mesoscale Quick Plex SQ 120mm 读取器的设备补充申请

• 批准号: 10173094
• 负责人: Tammy Regena Ozment
• 金额: $ 5.99万
• 依托单位: EAST TENNESSEE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10173094
• 关键词: Administrative Supplement; Award; Biological Markers; Cells; Clinical; Complex; Critical Illness; Detection; Diagnosis; Disease; Equipment; Event; FDA approved; Failure; Functional disorder; Funding; Goals; Human; Immune; Immune System Diseases; Immune response; Immune system; Immunosuppression; Leukocytes; Molecular; Multiple Organ Failure; Mycoses; National Institute of General Medical Sciences; Organ; Parents; Patients; Pharmaceutical Preparations; Reader; Research; Secondary to; Sepsis; Sepsis Syndrome; Septic Shock; Systemic Inflammatory Response Syndrome; United States; chemokine; cytokine; effective therapy; equipment acquisition; mortality; new therapeutic target; prevent; programs; response; secondary infection; septic; septic patients

This administrative supplement request to purchase equipment is being submitted in response to PA-18-591 (NIGMS Program of Administrative Supplements for Equipment). My currently funded R01 GM122934 is the parent award for this supplemental request. I am requesting funding for a Mesoscale QuickPlex SQ 120. The critically ill patient frequently develops a complex disease spectrum that may include systemic inflammatory response syndrome, sepsis syndrome, septic shock and/or multiple organ dysfunction syndrome. In the United States ~951,000 patients/year develop sepsis with approximately half of these patients in the ICU. The overall mortality rate is 28.6%. Those patients that survive the initial septic event may ultimately succumb to widespread organ dysfunction due to ongoing immune dysfunction. It is well accepted that sepsis causes suppression of the immune system, and that sepsis-induced immunoparalysis predisposes the critically ill patient to secondary infections. Secondary fungal infections are one of the most serious, as they are difficult to diagnose and treat. Attempts at developing effective therapies to prevent or treat sepsis and its associated immunosuppression have proven to be exceedingly difficult. In fact, no drugs are currently approved by the FDA for the management of sepsis. A very important aspect of this research is to establish the impact of sepsis on leukocytes and innate immune parameters in sepsis. To achieve this goal, we will critically analyze cytokines, chemokines and biomarkers from sepsis patients. This will require a detection sensitivity and dynamic range that is far beyond our current capabilities. The Mesoscale QuickPlex SQ 120 that is requested in this supplement will fill this critical and unmet need. In addition, the increase capabilities of the SQ 120 will allow us to more critically evaluate our working hypotheses.

这一采购设备的行政补充申请是根据PA-18-591提交的 （NIGMS设备管理补充计划）。我目前资助的R 01 GM 122934是 此补充请求的父奖励。我申请资金用于中型快速反应器 120.重症患者经常发展为复杂的疾病谱，可能包括全身性 炎症反应综合征、脓毒症综合征、脓毒性休克和/或多器官功能障碍 综合征在美国，每年约有951，000例患者发生脓毒症，其中约有一半 ICU里的病人总死亡率为28.6%。那些在最初的脓毒症事件中存活下来的患者 可能最终由于持续的免疫功能障碍而导致广泛的器官功能障碍。公 接受脓毒症导致免疫系统抑制，脓毒症诱导的免疫麻痹 使重症患者易于继发感染。继发性真菌感染是最常见的 严重的，因为它们很难诊断和治疗。尝试开发有效的治疗方法，以预防或 治疗脓毒症及其相关免疫抑制已被证明是极其困难的。事实上，没有药物 目前已被FDA批准用于治疗败血症。这项研究的一个非常重要的方面是 目的是确定脓毒症对白细胞和先天免疫参数的影响。实现这一 我们将严格分析脓毒症患者的细胞因子、趋化因子和生物标志物。这将需要 检测灵敏度和动态范围远远超出了我们目前的能力。中尺度 本补充材料中要求的QuickSocks SQ 120将满足这一关键和未满足的需求。此外该 SQ 120能力的提高将使我们能够更严格地评估我们的工作假设。